Compound 18, also known as FLT3/CHK-IN-1, is a dual inhibitor targeting FLT3 and CHK1, exhibiting over 1700-fold selectivity towards c-KIT and significantly diminishing hERG affinity, with an IC50 of 58.4 µM. It demonstrates efficacy in suppressing tumor
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted